Member Info for Yorkshirepragma

Https://www.biopharmadive.com/news/biotech-pharma-deals-merger-acquisitions-tracker/604262/

Recent deals inn$1bn+ illustrate buyers nt unhappy to ‘ go early’ without full phase 2 etc , provided reasonable prospect.

A variation such as 6000 must have reduced risk, as it has an inherent market to present itself into. As a few more I’s are dotted expect we’ll see,

Commercial Director reported ‘ very busy …if he were here he’d tell you’ I recall?

GL

Looks like the altruistic runners just giving has gone?

Https://www.gsacapital.com/who-we-are

Words fail me….no sign of ‘ ethical values ‘ on their site . Sad bunch.

Their CEO might need a few more cashews to chew on.

See their site

Different sector but Merck declared as needing replacement Chemo drugs .

EyeBio sold to Merck for up to $3bn

https://www.thetimes.co.uk/article/1b9369c3-8d60-404c-be4e-8eca2fbb6cb0?shareToken=f05deb583fa9c93c1ba12e0c8d196e06

Https://sharetipstersuncovered.wordpress.com/2015/01/02/is-tom-winnifrith-the-biggest-loser-ever/

Great track record?

Am sure this is a statement , but it’s clear a ‘ treatment jump’ as they say in the ‘trade’.

Particularly relevant is the low cardio effect potential ,which in the case of children being treated is a mega concern. Dilemma being it’s a great treatment, however this side effects a huge negative.

I forget the numbers of children which are treated annually, but cutting out this negative effect and at the same time providing an albeit selective( high FAP) more efficacious Dox treatment ,would be a life saver.

I sincerely hope this is taken to the nth degree ,am sure the CEO et al intends to do so as an intelligent, capable physician.

A great step potentially.

Regards

Or of course …a development deal…val. anyone’s guess. But see details of similar Antibody conjugate dev deals to date.

Let’s see what the commercial dir3ctor has been up to, as CEO says..he’s been busy!

GLA

$1.8 bn …stage 1/2

https://www.biopharmadive.com/news/genmab-profoundbio-adc-acquisition-buyout-seagen/712097/

Tim, that would be a spectacular step forward on contributing to oncology outcomes…from exp.

Here’s hoping it’s to be there to assist folk with a kinder better treatment.

Highly additive..

Regards

Few weeks I. Bringing decent drive as well as scientific & commercial ability…superb.

NFTs.

Notably the most relevant point for parient awaiters!

Majority of purchased later stagers ( in 24) ,and similarities with Av.

CEO openly stated Development of commercial links ‘ very busy ‘.

Let’s see what it’s worth at this stage.

My take AS not in agreement with deals coming forward at this point.

Time will tell..

GLA

W, rush of potential .bravo.

&AZ one of several BP with an appetite.

CEO in for a short while ,but USA style ,so will not likely be long before we see some fireworks.

GLA

Fortunately ba hybrid production set up. Can be switched to AFFIMER DCS.

Wyn, unless a previous Biotech CEO , and your view a little ultra crepidarian?

GSAs CEO David Khabie-Zeitoune, publicises his charitable works , at the same time his company shorts a developing cancer drug developer, to its detriment.

What a great chap!

& there’s not many BP without an oncology search.

H. Incoming results are the starter gun. Many will be watching!

Best parallel ,M& A at stage 1 …then $1-2 bn , increasing thereafter ,subject to continued tech success.

If a decent ( any) offer emerges it’ll be already punted . Pharma a club,

GLA

Yup…Nasdaq here we come..